Decide with Clarity

Global Pricing and Market Access

About the RxData platform

Less Stress, More Market Access

With RxData, conduct your analogue analysis with peace of mind! Clear information with holistic views of key product life-cycle events:

  • Regulatory decisions
  • HTA Publications
  • Reimbursement decisions
  • Global list prices

All-in-one solution for market access, pricing and reimbursement

With live monitoring of more than 100 data sources, RxData is the most complete repository of market access intelligence. RxData has detailed market access information presented in a simple way.

  • 3 simple views: Events, Coverage and Pricing
  • Search by Drugs, Indications or Manufacturers
  • Exportable Market Access dashboards

A must-have solution to gain a competitive edge

Better data yields better insights:

  • Curated HTA and regulatory data
  • List prices powered by visible net price algorithms
  • Thanks to automation, find results for ANY prescription drug

Reduce research time by up to 95%

With RxData, go-to-market faster:

  • Make better decisions and fewer costly mistakes
  • Have a finger on the pulse using real-time data
  • Lower research costs by up to 70% and go faster and with fewer resources by avoiding a new project every time
  • Access an internal repository to keep the knowledge in-house and gain competitive advantage

What's your case?

  • Phase 2/3 Transition (1)
  • Phase 2/3 Transition (2)
  • In License (1)
  • In License (2)
  • Value Dossier
  • Pricing (1)
  • Pricing (2)

Phase 2/3 Transition

Company A has a small molecule that has demonstrated activity across a range of tumors in Phase 2 and is finalizing Phase 3 strategy. Ultimately the company is looking to maximize lifetime value of the asset. The company intends to model the value of each potential indication (accounting for potential price, size of opportunity and competitive intensity) and then analyze whether lifetime value is enhanced by sequencing smaller but higher priced indications first vs. focusing on the largest potential indication.

Phase 2/3 Transition

Using RxData, the company is able to quickly and reliably forecast pricing assumptions for each potential indication in each of the top 12 target markets (US, Japan, EU5, China, Brazil, Mexico, Canada and Australia). Without RxData, this would have required a consulting engagement with a specialized firm that would cost over $1MM and take 3-4 months to complete.

In License

Company B is working on a licensing deal for a phase 3-ready molecule in the immuno-oncology market. While the company know oncology, they are relatively new to immuno-oncology and therefore have limited internal commercialization and market access expertise. The deal team need an assessment of what data / differentiation will be required to secure market access in the major markets in the 3 year horizon. The deal process is very competitive and time is of the essence.

In License

Using RxData, the deal team was able to quickly understand the level of differentiation that is presently required to achieve good access and pricing. The deal team was able to project how the competitive landscape would likely evolve and where the deal asset would fit from a competitive / market access perspective in the major global markets. Without RxData, the deal team would've been time-constrained to get any meaningful data. Traditional consulting agencies would've not been able to design, deploy and report a project on such a short timeline and would've relied on the subjective assessment of non-expert internal employees or a few interviews with external experts.

Value Dossier

Company C has completed phase 3 development work for a NME to treat (pick a disease) and has filed with all major regulatory agencies with approvals anticipated within 9-18 months. Before finalizing the key arguments in the Value Dossier, the company wants an up-to-date survey all HTA decisions in the disease area. Using RxData, the company was able to immediately review all relevant Market Access decisions in the top 10 markets, including the data and arguments presented by competitive products. Without RxData, this work would have required a consulting engagement with a specialized firm that would cost over $0.5MM and take 1-2 months to complete.

Pricing

Company D is working on the first oral agent for a IV/injectable dominated therapeutic area. The current branded IV products in the market place have seen significant market erosion due to off-label use of much cheaper biosimilar, indicated for a different therapeutic area. Company D must determine the ideal pricing model for its oral compound, given the market dynamics in that therapeutic market space.

Pricing

Using RxData, Company D was able to assess analogues in the US and EU of an oral agent entering an IV market area with existing market share and price erosion to determine the optimal pricing strategy for its unique mode of delivery. The research, based on access to RxData's critical resources, was presented to Company D's International Development Committee for rapid assessment of that compound’s R&D viability. Without RxData, the team would've had to deploy global pricing market research and subsequent reimbursement analysis, which would have taken months compared to a few days using RxData.